(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/049345 A1

(51) International Patent Classification:
A61P 29/00 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2024/043755

(22) International Filing Date:
23 August 2024 (23.08.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/578,946 25 August 2023 (25.08.2023) US

(71) Applicant: **PROTEOLOGIX US INC.** [US/US]; 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US).

(72) Inventors: **ZHENG, Yan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **TANG, Jie**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **WANG, Yan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **ZHANG, Rui**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **XU, Minghui**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **SHEN, Wenyan**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US). **TANG, Danming**; c/o Proteologix US Inc., 1400 Bridge Pkwy, Suite 202, Redwood City, CA 94065 (US).

(74) Agent: **COHEN, Adrienne, O.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-IL-13 MULTISPECIFIC ANTIBODY CONSTRUCTS AND USES THEREOF

FIG. 18C



(57) Abstract: The present invention relates to multispecific constructs that specifically bind to IL- 13 and a second target antigen (*e.g.*, TSLP, IL-17A, IL-17F, TNF-α, and IFN-γ). Also provided are antibody constructs that specifically bind to IL-13. Compositions, kits, methods of use (*e.g.*, treating inflammatory disease), and methods of making thereof are also provided.

WO 2025/049345 A1